Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03912064
Recruitment Status : Recruiting
First Posted : April 11, 2019
Last Update Posted : July 23, 2019
Sponsor:
Information provided by (Responsible Party):
John Koreth, MD, Dana-Farber Cancer Institute

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : April 26, 2022
Estimated Study Completion Date : May 31, 2024